Liquidia (NASDAQ:LQDA) Director Raman Singh Sells 29,494 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) Director Raman Singh sold 29,494 shares of the business’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $60.13, for a total transaction of $1,773,474.22. Following the completion of the sale, the director directly owned 38,755 shares of the company’s stock, valued at approximately $2,330,338.15. This trade represents a 43.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Liquidia Price Performance

Shares of LQDA opened at $60.10 on Wednesday. Liquidia Corporation has a 1-year low of $11.85 and a 1-year high of $62.30. The stock has a market cap of $5.34 billion, a PE ratio of 429.32 and a beta of 0.41. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. The firm has a fifty day moving average price of $43.00 and a 200 day moving average price of $37.80.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. The firm had revenue of $132.87 million during the quarter, compared to analysts’ expectations of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.Liquidia’s revenue for the quarter was up 4187.1% on a year-over-year basis. As a group, sell-side analysts anticipate that Liquidia Corporation will post 2.97 EPS for the current year.

Institutional Trading of Liquidia

Hedge funds have recently added to or reduced their stakes in the stock. Caprock Group LLC acquired a new stake in Liquidia during the 3rd quarter worth approximately $37,114,000. Federated Hermes Inc. acquired a new stake in Liquidia during the 3rd quarter worth approximately $7,290,000. Apis Capital Advisors LLC acquired a new stake in Liquidia during the 3rd quarter worth approximately $9,569,000. Farallon Capital Management LLC lifted its position in Liquidia by 102.1% during the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock worth $194,783,000 after acquiring an additional 4,326,876 shares during the period. Finally, GSA Capital Partners LLP lifted its position in Liquidia by 63.6% during the 4th quarter. GSA Capital Partners LLP now owns 63,176 shares of the company’s stock worth $2,179,000 after acquiring an additional 24,555 shares during the period. 64.54% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

LQDA has been the subject of a number of research analyst reports. Wells Fargo & Company upped their target price on Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th. Oppenheimer upped their target price on Liquidia from $16.00 to $19.00 and gave the company an “underperform” rating in a research report on Thursday, March 12th. HC Wainwright upped their target price on Liquidia from $55.00 to $67.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. Wall Street Zen raised Liquidia from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 16th. Finally, Raymond James Financial reissued a “strong-buy” rating on shares of Liquidia in a research report on Thursday, March 5th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.33.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).